1 Genomic characterization of invasive typhoidal and non-typhoidal *Salmonella* in

2 southwestern Nigeria

3
4 Odion O. Ikhimiukor¹, Anderson O. Oaikhen¹, Ayorinde O. Afolayan¹, Abayomi Fadeyi²,
5 Aderemi Kehinde³, Victoria Ogunleye³, Aaron O. Aboderin⁴, Oyinlola O. Oduyebo⁵, Charles
6 J. Elikwu⁶, Erkison Ewomazino Odih¹, Ifeoluwa Komolafe¹, Silvia Argimón⁷, Abiodun
7 Egwuenu⁸, Ini Adebisi³, Oluwadamilola A. Sadare⁶, Tochi Okwor⁸, Mihir Kekre⁷, Anthony
8 Underwood⁷, Chikwe Ihekweazu⁸, David M. Aanensen⁷ and Iruka N. Okeke¹

9
10
11 ¹ Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance,
12 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan,
13 Ibadan, Oyo State, Nigeria.

14 ² Department of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara
15 State, Nigeria.

16 ³ Department of Medical Microbiology and Parasitology, University College Hospital,
17 Ibadan, Oyo State, Nigeria.

18 ⁴ Department of Medical Microbiology and Parasitology, Obafemi Awolowo University
19 Teaching Hospitals Complex, Ile-Ife, Nigeria.

20 ⁵ Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences,
21 College of Medicine, University of Lagos, Lagos, Nigeria

22 ⁶ Department of Medical Microbiology, School of Basic Clinical Sciences, Benjamin Carson
23 College of Health and Medical Sciences, Babcock University & Teaching Hospital, Ilishan-
24 Remo, Ogun State, Nigeria.

25 ⁷ Centre for Genomic Pathogen Surveillance, Big Data Institute, University of Oxford,
26 Oxford, United Kingdom.

27 ⁸ Nigeria Centre for Disease Control, Jabi, Abuja, Nigeria.

28 ABSTRACT

29 **Background:** Salmonellosis causes significant morbidity and mortality in Africa. Despite
30 being endemic in Nigeria, information on circulating lineages of invasive *Salmonella* is
31 sparse.

32 **Methods:** Sixty-three *Salmonella enterica* isolated from blood (n=60) and cerebrospinal fluid
33 (CSF, n=3) isolated between 2016 and 2020 from five tertiary hospitals in southwest Nigeria
34 were Illumina-sequenced and analysed using publicly available bioinformatic tools.

35 **Results:** Isolates and sequence types (STs) from blood were *S. Typhi* [ST1 =1 and ST2 =43]
36 and invasive non-typhoidal *Salmonella* (iNTS) (*S. Enteritidis* [ST11, n=7], *S. Durham* [ST10,
37 n=2], *S. Rissen* [ST8756, n=2], *S. Chester* [ST2063, n=1], *S. Dublin* [ST10, n=1], *S. Infantis*
38 [ST603, n=1], *S. Telelkebir* [ST8757, n=1] and *S. Typhimurium* [ST313, n=1], whereas it
39 was *S. Typhi* ST2 (n=2) and *S. Adabraka* ST8757 (n=1) from CSF. Most *S. Typhi* belonged
40 to genotype 3.1.1 (n=44, 95.7%) and had several antibiotic resistance genes (ARGs)
41 including *bla*_{TEM-1} (86.4%, n=38), *aph*(6)-*Id* (72.7%, n=32), *tet*(A) (75%, n=33), *sul2* (72.7%,
42 n=32), *dfrA14* (68.18%, n=30) as well as the quinolone resistance-conferring *gyrA*_{S83Y}
43 SNPs (n=37, 84.09%). The 3.1.1 strains included a predominant sub-lineage (n=33)
44 harbouring *gyrA*_{S83Y} and an IncY plasmid detected at all hospitals. Typhoidal toxins *cdtB*,
45 *pltA* and *pltB* were detected in *S. Typhi*, Rissen, Chester, and Telelkebir.

46 **Conclusion:**

47 This study revealed the West African dominant lineage 3.1.1 to be majority of *S. Typhi*
48 genotype harbouring ARGs. The increasing number of iNTS, including serovars harbouring
49 typhoidal toxins, as well as the dominance of multidrug resistant isolates emphasizes the need
50 for better diagnosis and surveillance of invasive *Salmonella*.

51

52

53

54 **Author Summary**

55 Whole genome sequencing of 63 invasive *Salmonella* from 5 tertiary hospitals in Nigeria
56 revealed multiple serovars including a dominant antibiotic-resistance-gene harbouring *S.*
57 Typhi 3.1.1 genotype comprising a *gyrA_S83Y* and IncY plasmid. We also report invasive
58 non-typhoidal *Salmonella* harbouring typhoidal toxins.

59

60

61 INTRODUCTION

62 *Salmonella* are a group of Gram negative, motile, facultative anaerobic rod-shaped bacteria
 63 belonging to the Enterobacteriaceae family. This genus consists of two known species,
 64 *Salmonella enterica* and *Salmonella bongori*. *S. enterica* are further distributed across six
 65 subspecies, of which the *S. enterica* subsp. *enterica* are most reported in infections involving
 66 homeotherm animals (1). Furthermore, *S. enterica* subsp. *enterica* consists of over 1500
 67 serovars differentiated by distinct antigenic specificity (2). The human host adapted *S.*
 68 *enterica* subsp. *enterica* serovars are usually associated with three marked clinical
 69 syndromes. *Salmonella enterica* subsp. *enterica* serovar Typhi cause typhoid fever, and the
 70 non-typhoidal *Salmonella* (NTS) cause bacteraemia and gastroenteritis in
 71 immunocompromised (including persons with advanced HIV disease, cases of severe malaria
 72 and malnutrition in children) and immunocompetent persons, respectively (3,4). *S. Paratyphi*
 73 produce a syndrome similar to typhoid fever.

74 The public health impact of *Salmonella* infections is significant particularly in Africa and
 75 Asia where they have a great influence on morbidity and mortality (5,6). For instance, an
 76 estimated 17.8 million cases of typhoid fever occur each year in low and middle-income
 77 countries (LMICs) (7). An earlier estimate suggests that the burden of typhoid fever is >100
 78 per 100000 individuals per annum in sub-Saharan Africa with an associated 1% mortality
 79 (8,9). Furthermore, an estimated 26% (33,490 lives lost) of the annual global typhoid-related
 80 mortality is reported to occur in Africa (9). The disease burden of typhoid in Nigeria is
 81 estimated at 364,791 typhoid cases resulting in 4,232 deaths (affecting 68% of individuals
 82 under 15 years of age) as at 2016 (10), however population-based data are only just becoming
 83 available (11). On the other hand, globally, NTS is estimated to cause approximately 94
 84 million cases of gastroenteritis per annum worldwide with a resultant mortality of 155,000
 85 (12). In immunocompromised cases of the disease (amongst HIV-positive adults), NTS is

86 reported to cause a 20% case fatality (212,000 deaths) in sub-Saharan Africa (SSA) annually,
87 while also being responsible for over 1 million cases of bloodstream infections in children in
88 SSA with a case fatality of 18.1% (197,000 child mortality) (4,13,14).

89 Although available reports suggest infection with *Salmonella enterica* to be the most
90 common cause of bloodstream infections in Africa (15), the incidence and microbiology of
91 typhoidal and invasive non-typhoidal *Salmonella* (iNTS) is still poorly understood. Many
92 regions on the continent have garnered little or no attention in the literature (7). Blood
93 culture-based surveillance represent standard methods for assessing the epidemiology and
94 aetiology of the invasive infections (16). However, limited surveillance of invasive
95 *Salmonella* on the Africa continent is majorly due to financial, logistical, and infrastructural
96 constraints for the institution of blood culture-based surveillance systems in the region
97 (7,8,16,17).

98 Such limitations not only obscure the true burden and prevalence of invasive *Salmonella*
99 infections in resource limited settings but also limit opportunity for genomic surveillance of
100 this pathogen. For instance, despite the huge burden of typhoid infections in Nigeria, there
101 are only 131 *Salmonella* genomes (all *S. Typhi*) from the country on Pathogenwatch
102 (<https://pathogen.watch/>, 15th November 2021) (18), a web-based platform for surveillance
103 of microbial genomes all of which were collected on or before 2013, and most from only two
104 centres. Lack of genomic surveillance information of invasive *Salmonella* in resource-limited
105 countries, including Nigeria, may deter interventions necessary to ameliorate this burden,
106 such as the typhoid conjugate vaccines (8,19,20). Hence, this report provides genomic
107 characterization of 2016-2020 invasive *Salmonella* retrieved from tertiary hospitals enrolled
108 into Nigeria's Antimicrobial Surveillance Network coordinated by the Nigeria Centre for
109 Disease Control (NCDC).

111

112 *MATERIALS AND METHODS*

113 **Ethical considerations**

114 Isolates were obtained as part of the surveillance efforts in line with Nigeria's national action
115 plan. Ethical approval for using them in research was obtained from the University of
116 Ibadan/University College Hospital ethics committee (UI/EC/15/093).

117

118 **Isolate collection and Identification**

119 Tertiary hospitals located in southwest Nigeria and enrolled into the Nigeria Antimicrobial
120 Surveillance Network provided cryopreserved isolates from blood and cerebrospinal fluid to
121 the AMR National reference laboratory. The isolates were from batched periods of 2016-
122 2018 (retrospective isolates), 2019 and 2020. The national reference lab in partnership with
123 the Global Health Research Unit for the Genomic Surveillance of Antimicrobial Resistance
124 (GHRU-GSAR) conducted the re-identification of the isolates using a VITEK 2 systems
125 (version 2.0, Biomérieux).

126

127 **DNA extraction and Library preparation**

128 The isolates were processed for the extraction of genomic DNA using Wizard DNA
129 extraction kit (Promega; Wisconsin, USA) following manufacturer's instructions. The
130 extracted DNA was quantified on a Qubit fluorometer (Invitrogen; California, USA) using
131 dsDNA Broad Range quantification assay. Double-stranded DNA libraries were prepared
132 using the Covaris LC220 for fragmentation, and NEBNext Ultra II FS DNA library kit for
133 Illumina with 384-unique indexes (New England Biolabs, Massachusetts, USA; Cat. No:
134 E6617L). Libraries were sequenced on an Illumina HiSeq X10 (Illumina, CA, USA).

135

136

137 **Genome Assembly**

138 Generated sequence reads from Illumina runs were *de novo* assembled following GHRU
139 protocols (<https://gitlab.com/cgps/ghru/pipelines/dsl2/pipelines/assembly>) using a Nextflow
140 workflow which inclusively comprises of adapter trimming (trimmomatic v0.38),
141 contamination detection (ConFindr v0.7.2), assembly (SPAdes v3.12.0), Quality Control
142 (multiqc v1.7, qualifyr v1.4.4) and Bactinspector (v 0.1.3).

143

144 **Sequence typing of *Salmonella* genomes**

145 Sequence reads were deposited in the *Salmonella* database on Enterobase (Zhou et al., 2020).
146 Multi-locus sequence types (MLST) for the isolates were determined and core-genome
147 MLST calculated. Evolutionary relationship based on cgMLST of all *S. Typhi* of human
148 origin from Africa deposited in Enterobase were determined (Zhou et al., 2020). The
149 *Salmonella* genome assemblies were analysed using the *Salmonella* In-Silico Typing
150 Resource (SISTR) for the prediction of serovars and serogroups ([https://github.com/phac-](https://github.com/phac-nml/sistr_cmd)
151 [nml/sistr_cmd](https://github.com/phac-nml/sistr_cmd)). Serovars belonging to *S. Typhi* were loaded unto pathogen watch for the
152 prediction of their genotypes (Argimón et al., 2021).

153

154 **Prediction of AMR, Plasmids, Virulence and *Salmonella* Pathogenicity islands**

155 Prediction of AMR and virulence determinants, multi-locus sequence types (MLST) and
156 plasmid replicons were done following GHRU protocols
157 (<https://gitlab.com/cgps/ghru/pipelines>). Prediction of salmonella pathogenicity islands (SPIs)
158 in the genomes was done by mapping raw reads to SPIs database
159 (https://bitbucket.org/genomicepidemiology/spifinder_db)

160

161

162 **Single Nucleotide Polymorphism (SNP) calling and phylogeny**

163 The sequence reads of the *Salmonella* genomes from our study were mapped to NCBI
164 reference sequence, *Salmonella enterica* subsp. *enterica* serovar Typhi strain H12ESR00755-
165 001A (Assembly accession: GCF_001362195.2), to determine evolutionary relationship
166 amongst the strains following GHRU nextflow SNP phylogeny protocols
167 (https://gitlab.com/cgps/ghru/pipelines/snp_phylogeny). SNP distances between the genome
168 pairs were calculated using snp-dists (<https://github.com/tseemann/snp-dists>) on the pseudo-
169 genome alignment.

170

171 **Availability of sequence data**

172 Raw sequence data generated from this study are deposited in the European Nucleotide
173 Archive under Bioproject PRJEB29739. Accession numbers for each genomes are available
174 as Supplementary information.

175

176 **RESULTS**

177 **Invasive *Salmonella* from sentinel hospitals from Nigeria's AMR Surveillance Network**

178 A total of 69 invasive and presumptive *Salmonella* spp. identified using VITEK at the
179 reference laboratory were retrieved from patients from five (n=5) sentinel hospitals.
180 However, whole-genome sequencing confirmed 61 of these to be *Salmonella enterica*, as
181 well as two *Salmonella enterica* isolates initially identified as *Escherichia coli* and
182 *Acinetobacter baumannii* using VITEK. (Five VITEK-identified '*Salmonella*' were *Klebsiella*
183 spp and one an *Enterobacter* spp. Strain). The sixty-three (63) WGS-confirmed invasive
184 *Salmonella* isolates were retrieved from blood (n=60) and cerebrospinal fluid (n=3). The
185 sending sentinel hospitals include: University of Ilorin Teaching Hospital (ILO, Ilorin, Kwara

State, n=25), University College Hospital, Ibadan (UCH, Ibadan, Oyo State, n=23), Obafemi Awolowo University Teaching Hospital, Ile-Ife (OAU, Ile-Ife, Osun State, n=8), Lagos University Teaching Hospital (LUT, Idi-Araba, Lagos State, n=4) and Babcock University Teaching Hospital (BUT, Ilishan-Remo, Ogun State, n=3). The hospitals are all in the southwestern part of Nigeria with ILO just north of the South-West geopolitical zone and all the rest within it. All the *Salmonella* isolates from cerebrospinal fluid were obtained from LUT.

Distribution of *Salmonella enterica* subsp. *enterica* serovars across sentinel hospitals

All the *Salmonella enterica* isolates belonged to the subspecies *enterica* but differed by serotype with a total of 10 serovars detected. They include Typhi (n=46), Enteritidis (n=7), Durham (n=2), Rissen (n=2), Adabraka (n=1), Chester (n=1), Dublin (n=1), Infantis (n=1), Telelkebir (n=1), Typhimurium (n=1). Three *Salmonella enterica* isolates belonging to serovars Adabraka (n=1) and Typhi (n=2) were retrieved from cerebrospinal fluid from LUT. All other *Salmonella* serovars were retrieved by blood culture at the respective sentinel sites (Supplementary data 1). *Salmonella* Typhi and iNTS were recovered from all sentinel sites, with iNTS being much less frequently recovered. Among the iNTS, *S. Enteritidis* was the most ubiquitous, being recovered in three of the five sentinels. The other iNTS serovars recovered more than once were *S. Rissen* =2 and *S. Durham* =2, both from UCH, which had the broadest range of iNTS serovars (4).

Sequence types, genotypes, and Nucleotide polymorphisms.

Salmonella sequence-typing based on Achtman's MLST scheme (21) identified two *S. Typhi* Sequence Types (STs) (ST1 =1 and ST2 = 45). There were nine different iNTS STs. These included previously reported invasive STs: *S. Enteritidis* ST11 (n=7) and *S. Typhimurium*

ST313 (n=1), which are repeatedly reported from Africa. Other iNTS were *S. Dublin* (ST10), *S. Enteritidis* (ST11), *S. Typhimurium* (ST313), *S. Infantis* (ST603), *S. Durham* (ST2010), *S. Chester* (ST2063), *S. Telelkebir* (ST2222). Two novel STs belonging to *S. Rissen* and *S. Adabraka* were curated and designated STs 8756 and 8757 respectively by EnteroBase.

To further place our *S. Typhi* genomes in a wider context, we performed MLST analysis based on differences in core genomes of our strains and all *S. Typhi* from Human sources in Africa deposited in EnteroBase (Fig 1). *S. Typhi* genomes from this study clustered with others from West Africa, including Nigeria, Cameroon, Togo, Mauritania, Mali, Burkina Faso, Guinea, Benin, and Ivory Coast, emphasizing further on their endemicity in the West Africa region (Fig 1).

Further, based on *S. Typhi* genotyping scheme, we observed that *S. Typhi* ST1 belonged to genotype 4.1 (UCH), whereas genotypes 2.3.1 (n=1, UCH) and 3.1.1 (n= 44) were *S. Typhi* ST2 isolates. In addition, *S. Typhi* genomes from CSF (n=2) belonged to the 3.1.1 genotype. Expectedly, *S. Typhi* genotypes 2.3.1 and 4.1 accounted for greatest pairwise SNP difference among the *S. Typhi* genomes (between 397 to 549 single nucleotide substitutions), whereas SNP differences ranged between 0 and 47 in the other *S. Typhi* genomes (genotype 3.1.1) from the 5 sentinel hospitals. Among *S. Enteritidis* pairwise SNP difference ranged from 0 to 37 in the three sentinel labs (UCH, OAU, ILO) where they were isolated. *S. Enteritidis* isolates from ILO (n=3) were near identical having pairwise SNP range from 0 to 1, whereas it was between 0 and 32 in UCH.

Antimicrobial resistance determinants and plasmids replicons in TS and NTS

A combined total of 14 acquired antimicrobial resistance genes (ARGs) conferring resistance to drugs within seven antibiotic classes were detected amongst the genomes (Fig 2, Supplementary data).

Amongst the *S. Typhi* genomes, 76.08% (n=36/46) harboured at least one ARG specifying reduced susceptibility to 5 antibiotic classes, with 89.13% harbouring a sulphonamide resistance gene [*sul1* – 19.56% (n=9/46), *sul2* – 71.73% (n=33/46)] and 84.78% (n=39/46) each harbouring a beta-lactam (*bla*_{TEM-1}), tetracyclines (*tetA* [n=33, 71.73%] and *tetB* [n=6, 13.04%]), and trimethoprim resistance determinant (*dfrA1* [n=1, 2.17%], *dfrA15* [n=8, 17.39%] and *dfrA14* [n=30, 65.21%]). In addition, quinolone resistance genes, *catA1*, were also detected in the genomes (n=8, 17.39%). Chromosomal gene mutations occurring among the sequenced *S. Typhi* isolates were those associated with the quinolone resistance determining region *gyrA*_S83Y SNPs (n=37, 84.09%), which mediate reduced susceptibility to fluoroquinolones. Furthermore, 97.82% (n=45) of the *S. Typhi* genomes had at least one plasmid predicted to occur in each genome. Majority (71.73%, n=33) possessed an IncY plasmid replicon, plasmid replicons IncFIA_HI1, IncHIA and IncHIB were respectively detected in 19.56% (n=9) of *S. Typhi* genomes whereas one isolate harboured an IncQ plasmid replicon.

For the iNTS, *S. Enteritidis* genomes possessed at least one ARG to six antibiotic classes. All Isolates of this serotype harboured *aph(3'')-Ib*, *bla*_{TEM-1}, *catA1*, *dfrA7*, *sul1*, *sul2*, *tet(B)* genes, and only differed in the absence/presence of *aph(6)-Id* (n=4, 57.14%). In tandem, *S. Typhimurium* harbour ARGs [*aadA1*, *aph(3'')-Ib*, *aph(6)-Id*, *bla*_{TEM-1}, *catA1*, *dfrA1*, *sul1*, *sul2*] specifying resistance to 5 antibiotic classes. The only occurring quinolone resistance gene among isolates in this study, *qnrB19*, was detected in *S. Telelkebir*. No ARGs were detected in *Salmonella* serovars Chester, Rissen, Durham, Infantis, Adabraka and Dublin. Chromosomal gene mutations among iNTS were associated with *gyrA* and *parC* gene regions. The quinolone resistance conferring *gyrA*_D87Y SNPs were detected only amongst *S. Enteritidis* (ILO = 3 and UCH = 1), whereas quinolone resistance conferring *parC*_T57S

SNPs were detected in all iNTS except *S. Enteritidis* and *S. Typhimurium*. Plasmids were predicted to occur only in *S. Dublin* [IncFII(S), IncX1 and IncX1_1], *S. Enteritidis* (IncI1 and IncQ1), *S. Typhimurium* [IncFIB, IncFII(S) and IncQ1] among the iNTS.

Predominant IncY + gyrA_S83Y harbouring *S. Typhi* variants in Nigeria

We observe that all *S. Typhi* of the 3.1.1 lineage harbouring an IncY plasmid replicon (71.73%, n=33/46) similarly possessed the *gyrA_S83Y* chromosomal gene mutation and harboured a *tetA* gene. This phenomenon was observed to occur in all the sentinel hospitals in this study. Additionally, pairwise SNP distance between the variants ranged from 0 to 18.

***Salmonella* virulence determinants and predicted pathogenicity islands**

The isolates possessed a plethora of virulence determinants (Supplementary data). Among the *S. Typhi* genomes, a total of 98 virulence determinants were detected, and 97 (98.97%) of these were conserved within members of this serovar (difference from the absence of *pipB2* gene in an *S. Typhi* 3.1.1 from UCH). Expectedly, a wider variety of virulence determinants were seen among iNTS, compared to *S. Typhi*. A total of 122 virulence genes were detected in the iNTS genomes, and 86 (70.49%) of these were conserved in all iNTS genomes. For instance, the iNTS possessed genes encoding (i) Adherence; such as AgF – thin aggregative fimbriae or curli (*csgABCDEGF*), MisL – an autotransporter protein, Pef – plasmid-encoded fimbriae (present only in *S. Typhimurium*) *ratB* (carried by iNTS strains harbouring CS54 islands), *shdA* (only found in *S. Infantis*), SinH (detected in all NTS except *S. Enteritidis*) and Type 1 fimbriae (*fimCDFHI*) (ii) Stress adaptation; *sodCI* – superoxide dismutase (detected in iNTS serovars except Durham, Chester and Rissen and *Infantis* and *Teitelkebir*), *sopA* (not detected in *S. Infantis*) (iii) Nutritional/metabolic factor (*mgtBC*, present in all strains) (iii) Antimicrobial activity/competitive advantage; such as macrophage inducible genes (*mig-14*,

present in all strains) and (iv) Enterotoxin; T3SS effectors – *spvB* (In *S. Typhimurium*, Enteritidis and Dublin), AvrA (In all iNTS except *S. Dublin*) and Typhoidal toxin - *cdtB* (present in *S. Durham*, *S. Telelkebir* and *S. Chester*).

Since the *cdtB* are reported to be co-located with other cytolethal distending toxins (*cdt*), pertussis-like toxins A (*pltA*) and B (*pltB*), on same pathogenicity islet (Simon et al., 2014), we ran a blast search of our strains for the presence of *pltA* and *pltB*. The nucleotide sequences were extracted from the virulence factor database (VFDB) and used as a local database for a blast search against our iNTS genomes. Our results reveal high similarity (100% coverage and $\geq 96.62\%$ identity) with *cdtB*, *pltA* and *pltB* genes in the iNTS genomes (*S. Chester*, *S. Durham* and *S. Telelkebir*).

Prediction of Salmonella pathogenicity islands (SPIs) gave 11 and 12 hits in *S. Typhi* and iNTS genomes respectively. All *S. Typhi* were predicted to have 10 SPIs, i.e., SPI-1, SPI-2, SPI-3, SPI-4, SPI-5, SPI-6, SPI-7, SPI-8, SPI-9, SPI-10 and SPI-12. However, SPI-4 was predicted to occur only in *S. Typhi* lineages 2.3.1 and 4.1. In contrast to *S. Typhi*, only SPI-3 was predicted to occur in all the iNTS genomes. SPIs were shown to be associated with members of certain serovars. For instance, SPI-2 and SPI-8 were detected only in *S. Typhimurium* and *S. Rissen*, respectively. Other pathogenicity islands were detected in this study (Fig 3, supplementary data), such as SPI-4 (*S. Adabraka*, *Chester*, *Typhimurium*), SPI-6 (all NTS except *S. Durham*, *Rissen* and *Telelkebir*), SPI-12 (all NTS except *S. Chester*, *Durham*, *Rissen* and *Telelkebir*) and CS54_island was detected in *S. Dublin*, *S. Typhimurium*, *S. Infantis* and *S. Enteritidis* (n=6/7, 85.71%).

Microreact main data:

<https://microreact.org/project/3tgJwQ1mPBkep3sv9QzRv6->

[ghrprojectinvasivesalmonella22-11-21](#)

Microreact SPIs:

<https://microreact.org/project/9M6qNGcvHNqwbjykmX9MaC-invasivesalmonellaspis>

DISCUSSION

In this report we present outcome of genomic characterization of invasive *Salmonella* infections from AMR surveillance in sentinel hospitals in Nigeria. The genomic characterization of invasive *Salmonella* isolates in this study was possible because these hospitals perform blood culture and enrolled in Nigeria's new antimicrobial resistance surveillance system, which offers genomic services at the National Reference Laboratory level (22). Nonetheless, blood culture is available at very few institutions in Nigeria, a limitation still prevalent in many African settings that impacts the genomic surveillance of invasive *Salmonella*. (8,16,23).

Using to high-throughput WGS and bioinformatic analytics, we were able to determine prevalent multiple serotypes and dominant genotypes of invasive *Salmonella* infections. Most of the isolates were *Salmonella* Typhi, which have been more frequently recovered in Nigeria (24,25), even though iNTS may predominate at other African settings (3,26). While our data are few, the predominance of Typhi at all sites points to a significant burden of severe disease that could be averted were Typhoid Conjugate Vaccines available in Nigeria. Out of a total of 10 *S. Typhi* genotypes recorded in Nigeria from Pathogenwatch, three were identified in this study. The prevalence of *S. Typhi* genotype 3.1.1 in our report was similarly observed in the Nigeria cluster on Pathogenwatch (n=87/131, 66.41%). As in our study, this cluster possessed similar prevalence of genetic determinants of beta-lactam (*bla*_{TEM-1} – 83.90%) resistance, indicating that these determinants are well-conserved in the genotype. However, prevalence of other AMR genetic determinants from this lineage such as *catA1* (86.20%),

sul1 (87.35%), *sul2* (3.44%), *dfrA14* (4.39%), *dfrA15* (87.35%), *tetA* (78.16%), *tetB* (78.16%) were not similar from what is reported from this study (*catA1* –18.18%, *sul1* – 18.18%, *sul2* – 72.72%, *dfrA14* – 68.18%, *dfrA15* – 18.18%, *tetA* – 75%, *tetB* – 11.36%).

This multidrug-resistance gene-encoding *S. Typhi* 3.1.1 is shown to be one of the broadest lineages in sub-Saharan Africa and endemic in the West Africa region (Wong et al., 2016; Park et al., 2018; Ingle et al., 2019). Additionally, we observed *S. Typhi* genotype 3.1.1 clone variants harbouring *IncY* + *gyrA_S83Y* + *tetA* genes. The Pathogenwatch database contains two strains isolated in Abuja, north-central part of the country in 2013 with similar clonal characteristics. Our data suggest that the resistant sublineage is predominant in our setting and should be sought elsewhere in Nigeria and the region.

S. Enteritidis were the most frequently recovered NTS in our study and were recovered at three sentinel hospitals. This outcome contrasts with earlier reports of *S. Typhimurium* ST313 in Eastern Africa, but also present across the continent, including Nigeria (15,27,28), but is concordant with more recent higher *S. Enteritidis* reports from invasive infections in The Gambia (29). We observed that *S. Enteritidis* retrieved from different patients in ILO (in 2019) had highly similar genetic features (antimicrobial resistance determinants, virulence, plasmids replicons) including pairwise SNP between 0 and 1. The isolates were recovered on the 27th of June, 26th of August and 28th of August 2019 and their genetic, geographic and temporal connectedness may be indicative of a previously unrecognized outbreak. Both *S. Typhimurium* ST313 and *S. Enteritidis* ST11 are dominant, human-adapted clones in sub-Saharan Africa (30) that are a major cause of invasive disease, with a corresponding high case-fatality rate (14). These serovars are justifiably vaccine development priorities.

Invasive NTS vaccines in the pipeline will not cover other NTS serovars and we identified several in this study, harbouring an assortment of virulence, plasmids and antimicrobial resistance determinants. This points to the need for widespread and robust access to invasive

Salmonella diagnostics in Nigeria. The single occurrence of an acquired quinolone resistance gene, qnrB19 in this study was detected in *S. Telelkebir*. To the best of our knowledge, this serovar has been reported just once on the African continent, in Mali (ENA accession number SRR8987873). However, it is more commonly reported in parts of Europe, China and USA (31). The expansion of atypical *Salmonella* serovars in invasive infections is associated with a high health burden (19,29).

We observed that NTS (*S. Telelkebir*, *S. Durham* and *S. Chester*) harboured the cytolethal distending toxin islet genes (*cdtB*, *pltA*, *pltB*) also known as typhoid toxin. These toxins were originally thought to be restricted to serovars Typhi and Paratyphi A (32). However, these have now been reported in other NTS serovars including Bredeney, Javiana, Montevideo, Schwarzengrund, and more recently in *Telelkebir* (33–35). The cytolethal distending toxin islet cause DNA damage and cell cycle arrest in impaired cells (36). More implicative, these genes encoded by NTS serovars have been reported to play vital roles in disease pathogenesis (34,35). Thus, this study emphasizes on an expanding number of serovars causing invasive infections in the country, and the public health implications therein.

CONCLUSION

The outcome of our study emphasizes the need for expanded genomic surveillance of invasive *Salmonella* infections in Nigeria as a valuable tool to monitor antibiotic resistance spread and genetic characterization of circulating lineages in Nigeria. Close monitoring of the antibiotic resistance genes harbouring *S. Typhi* 3.1.1 IncY + *gyrA*_S83Y variants and other serovars is vital, and this may inform strategies for empirical treatment and control of spread of antibiotic resistant lineages. Our data demonstrate that introducing typhoid conjugate vaccines, recommended by the World Health Organization for countries like Nigeria that have a high typhoid disease burden, will have a significant impact on health (37). In addition,

development of vaccines which target NTS would be useful in reducing the overall burden of NTS on the continent and rigorous surveillance is essential for determining which serovars most require coverage. Even broader protective effects may be achieved by improvements in water, sanitation and hygiene that could interrupt transmission of the causes of typhoid and other invasive salmonellosis.

ACKNOWLEDGEMENT

This work was supported by Official Development Assistance (ODA) funding from the National Institute of Health Research [grant number 16_136_111] and the Wellcome Trust grant number 206194. INO was an African Research Leader supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement that is also part of the EDCTP2 program supported by the European Union. The funders had no role in the content, crafting or submission of this paper.

We thank Chinenye Ekemezie and Ifeoluwa Akintayo for excellent technical contributions and Jola-Ade J. Ajiboye for logistic assistance. We are grateful to the administration and staff of the five sentinels for supporting them in surveillance.

REFERENCES

1. Giner-Lamia J, Vinuesa P, Betancor L, Silva C, Bisio J, Soleto L, et al. Genome analysis of *Salmonella enterica* subsp. *diarizonae* isolates from invasive human infections reveals enrichment of virulence-related functions in lineage ST1256. *BMC Genomics* [Internet]. 2019 Jan 31 [cited 2021 Nov 9];20(1):1–14. Available from:

<https://link.springer.com/articles/10.1186/s12864-018-5352-z>

2. Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, De Pinna E, Nair S, et al. Supplement 2008–2010 (no. 48) to the White–Kauffmann–Le Minor scheme. *Res Microbiol*. 2014 Sep 1;165(7):526–30.
3. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. *Lancet*. 2012 Jun 30;379(9835):2489–99.
4. Keestra-Gounder AM, Tsolis RM, Bäumlér AJ. Now you see me, now you don't: the interaction of Salmonella with innate immune receptors. *Nat Rev Microbiol* 2015 134 [Internet]. 2015 Mar 9 [cited 2021 Nov 9];13(4):206–16. Available from: <https://www.nature.com/articles/nrmicro3428>
5. Smith SI, Seriki & A, Ajayi & A. Typhoidal and non-typhoidal Salmonella infections in Africa. *Eur J Clin Microbiol Infect Dis*.
6. Phu Huong Lan N, Le Thi Phuong T, Nguyen Huu H, Thuy L, Mather AE, Park SE, et al. Invasive Non-typhoidal Salmonella Infections in Asia: Clinical Observations, Disease Outcome and Dominant Serovars from an Infectious Disease Hospital in Vietnam. *PLoS Negl Trop Dis* [Internet]. 2016 Aug 11 [cited 2022 Jan 4];10(8):e0004857. Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004857>
7. Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, et al. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. *PLoS Negl Trop Dis* [Internet]. 2017 Feb 27 [cited 2021 Nov 9];11(2):e0005376. Available from: <https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005376>
8. Crump JA, Heyderman RS. A Perspective on Invasive Salmonella Disease in Africa.

- Clin Infect Dis [Internet]. 2015 Nov 1 [cited 2021 Nov 2];61(suppl_4):S235–40.
Available from: https://academic.oup.com/cid/article/61/suppl_4/S235/458434
9. Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale V V., Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Heal. 2014 Oct 1;2(10):e570–80.
10. TyVAC. Potential of typhoid conjugate vaccines in Nigeria [Internet]. 2017. 2017 Nov [cited 2021 Nov 13]. Available from: https://www.coalitionagainststyphoid.org/wp-content/uploads/2017/11/TCV-country-specific-factsheet-Nigeria_final.pdf
11. Park SE, Toy T, Cruz Espinoza LM, Panzner U, Mogeni OD, Im J, et al. The Severe Typhoid Fever in Africa Program: Study Design and Methodology to Assess Disease Severity, Host Immunity, and Carriage Associated with Invasive Salmonellosis. Clin Infect Dis [Internet]. 2019 Oct 30 [cited 2021 Nov 2];69(Supplement_6):S422–34.
Available from: https://academic.oup.com/cid/article/69/Supplement_6/S422/5609450
12. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O’Brien SJ, et al. The global burden of nontyphoidal salmonella gastroenteritis. Clin Infect Dis [Internet]. 2010 Mar 15 [cited 2021 Nov 10];50(6):882–9. Available from: <https://academic.oup.com/cid/article/50/6/882/419872>
13. Gordon MA. Salmonella infections in immunocompromised adults. J Infect. 2008 Jun 1;56(6):413–22.
14. Reddy EA, Shaw A V., Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010 Jun 1;10(6):417–32.
15. Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. A Systematic Review and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections

among Hospitalized Patients in Africa and Asia. 2019 [cited 2021 Nov 9]; Available from: <https://doi.org/10.1128/AAC.01974-19>.

16. Ombelet S, Barbé B, Affolabi D, Ronat J-B, Lompo P, Lunguya O, et al. Best Practices of Blood Cultures in Low- and Middle-Income Countries. *Front Med* [Internet]. 2019 Jun 18 [cited 2021 Nov 11];6. Available from: [/pmc/articles/PMC6591475/](https://pubmed.ncbi.nlm.nih.gov/3591475/)
17. Balasubramanian R, Im J, Lee JS, Jeon HJ, Mogeni OD, Kim JH, et al. The global burden and epidemiology of invasive non-typhoidal Salmonella infections. <https://doi.org/10.1080/2164551520181504717> [Internet]. 2018 Jun 3 [cited 2021 Nov 26];15(6):1421–6. Available from: <https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1504717>
18. Argimón S, Yeats CA, Goater RJ, Abudahab K, Taylor B, Underwood A, et al. A global resource for genomic predictions of antimicrobial resistance and surveillance of Salmonella Typhi at pathogenwatch. *Nat Commun* 2021 121 [Internet]. 2021 May 17 [cited 2021 Nov 14];12(1):1–12. Available from: <https://www.nature.com/articles/s41467-021-23091-2>
19. Balasubramanian R, Im J, Lee JS, Jeon HJ, Mogeni OD, Kim JH, et al. The global burden and epidemiology of invasive non-typhoidal Salmonella infections. <https://doi.org/10.1080/2164551520181504717> [Internet]. 2018 Jun 3 [cited 2021 Nov 10];15(6):1421–6. Available from: <https://www.tandfonline.com/doi/abs/10.1080/21645515.2018.1504717>
20. Carey ME, Steele AD. The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines. *Clin Infect Dis* [Internet]. 2019 Oct 30 [cited 2021 Nov 26];69(Supplement_6):S413–6. Available from: https://academic.oup.com/cid/article/69/Supplement_6/S413/5609446

21. Achtman M, Wain J, Weill FX, Nair S, Zhou Z, Sangal V, et al. Multilocus Sequence Typing as a Replacement for Serotyping in *Salmonella enterica*. *PLOS Pathog* [Internet]. 2012 [cited 2022 Jan 20];8(6):e1002776. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002776>
22. Afolayan AO, Oaikhen A, Aboderin AO, Olabisi OF, Amupitan AA, Abiri O V, et al. Clones and Clusters of Antimicrobial-Resistant *Klebsiella* From Southwestern Nigeria. *Clin Infect Dis*. 2021;73(Supplement_4):S308–15.
23. Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA. Laboratory medicine in Africa: A barrier to effective health care. *Clin Infect Dis* [Internet]. 2006 Feb 1 [cited 2021 Nov 25];42(3):377–82. Available from: <https://academic.oup.com/cid/article/42/3/377/378561>
24. Obaro SK, Hassan-Hanga F, Olateju EK, Umoru D, Lawson L, Olanipekun G, et al. *Salmonella* Bacteremia Among Children in Central and Northwest Nigeria, 2008–2015. *Clin Infect Dis* [Internet]. 2015 Nov 1 [cited 2022 Jan 4];61(suppl_4):S325–31. Available from: https://academic.oup.com/cid/article/61/suppl_4/S325/459582
25. Popoola O, Kehinde A, Ogunleye V, Adewusi OJ, Toy T, Mogeni OD, et al. Bacteremia Among Febrile Patients Attending Selected Healthcare Facilities in Ibadan, Nigeria. *Clin Infect Dis* [Internet]. 2019 Oct 30 [cited 2022 Jan 4];69(Supplement_6):S466–73. Available from: https://academic.oup.com/cid/article/69/Supplement_6/S466/5609444
26. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of invasive nontyphoidal *Salmonella* disease, 2010(1). *Emerg Infect Dis* [Internet]. 2015 Jun 1 [cited 2022 Jan 4];21(6):941–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/25860298/>
27. Kingsley RA, Msefula CL, Thomson NR, Kariuki S, Holt KE, Gordon MA, et al.

- 510 Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in
511 sub-Saharan Africa have a distinct genotype. Genome Res [Internet]. 2009 Dec 1
512 [cited 2021 Nov 25];19(12):2279–87. Available from:
513 <https://genome.cshlp.org/content/19/12/2279.full>
- 514 28. Okoro CK, Kingsley RA, Connor TR, Harris SR, Parry CM, Al-Mashhadani MN, et
515 al. Intracontinental spread of human invasive Salmonella Typhimurium pathovariants
516 in sub-Saharan Africa. Nat Genet 2012 4411 [Internet]. 2012 Sep 30 [cited 2021 Nov
517 25];44(11):1215–21. Available from: <https://www.nature.com/articles/ng.2423>
- 518 29. Kante A, Sesay AK, Alikhan N-F, Ikumapayi UN, Salaudeen R, Manneh J, et al.
519 Invasive atypical non-typhoidal Salmonella serovars in The Gambia. Microb
520 Genomics [Internet]. 2021 Nov 23 [cited 2021 Nov 25];7(11):000677. Available from:
521 <https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000677>
- 522 30. Park SE, Pham DT, Pak GD, Panzner U, Espinoza LMC, Kalckreuth V von, et al. The
523 genomic epidemiology of multi-drug resistant invasive non-typhoidal Salmonella in
524 selected sub-Saharan African countries. BMJ Glob Heal [Internet]. 2021 Aug 1 [cited
525 2021 Nov 2];6(8):e005659. Available from: <https://gh.bmj.com/content/6/8/e005659>
- 526 31. Qiu YF, Nambiar RB, Xu X Bin, Weng ST, Pan H, Zheng KC, et al. Global Genomic
527 Characterization of Salmonella enterica Serovar Telekebir. Front Microbiol. 2021 Jul
528 29;12:2007.
- 529 32. Tamamura Y, Tanaka K, Uchida I. Characterization of pertussis-like toxin from
530 Salmonella spp. that catalyzes ADP-ribosylation of G proteins. Sci Reports 2017 71
531 [Internet]. 2017 Jun 1 [cited 2021 Nov 24];7(1):1–13. Available from:
532 <https://www.nature.com/articles/s41598-017-02517-2>
- 533 33. den Bakker HC, Moreno Switt AI, Govoni G, Cummings CA, Ranieri ML, Degoricija
534 L, et al. Genome sequencing reveals diversification of virulence factor content and

possible host adaptation in distinct subpopulations of *Salmonella enterica*. BMC Genomics [Internet]. 2011 Dec 22 [cited 2021 Nov 25];12(1):1–11. Available from: <https://bmcbgenomics.biomedcentral.com/articles/10.1186/1471-2164-12-425>

34. Mezal EH, Bae D, Khan AA. Detection and functionality of the CdtB, PltA, and PltB from *Salmonella enterica* serovar Javiana. Pathog Dis [Internet]. 2014 Nov 1 [cited 2021 Nov 25];72(2):95–103. Available from: <https://academic.oup.com/femspd/article/72/2/95/629542>

35. Rodriguez-Rivera LD, Bowen BM, Den Bakker HC, Duhamel GE, Wiedmann M. Characterization of the cytolethal distending toxin (typhoid toxin) in non-typhoidal *Salmonella* serovars. Gut Pathog [Internet]. 2015 Jul 24 [cited 2021 Nov 24];7(1):1–7. Available from: <https://gutpathogens.biomedcentral.com/articles/10.1186/s13099-015-0065-1>

36. Chang SJ, Jin SC, Jiao X, Galan JE. Unique features in the intracellular transport of typhoid toxin revealed by a genome-wide screen. PLOS Pathog [Internet]. 2019 [cited 2021 Nov 21];15(4):e1007704. Available from: <https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1007704>

37. WHO. WHO recommends use of first typhoid conjugate vaccine [Internet]. 2018 [cited 2021 Nov 26]. Available from: <https://www.who.int/news/item/03-04-2018-who-recommends-use-of-first-typhoid-conjugate-vaccine>

Figure Legends

Fig 1: Grape tree showing core genome MLST of *S. Typhi* from human sources in Africa, deposited in the EnteroBase database. Red leaf labels are genomes from this study

Fig 2: A SNP-phylogeny based tree and heatmap showing the genomic profile of *Salmonella* genomes retrieved from 5 sentinel laboratories in Nigeria

Fig 3: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal *Salmonella*) and NTS (Non-typhoidal *Salmonella*).

Fig 1: Grape tree showing core genome MLST of *S. Typhi* from human sources in Africa, deposited in the EnteroBase database. Red leaf labels are genomes from this study

Fig 3: Frequency of occurrence of *Salmonella* pathogenicity island in TS (Typhoidal Salmonella) and NTS (Non-typhoidal Salmonella).